Table 2. Comparison of characteristics of patients with the five most common mutations.
| Characteristics | No mutation (n=46) | EGFR (n=24) | KRAS (n=30) | MET (n=17) | PIK3CA (n=10) | TP35 (n=39) |
|---|---|---|---|---|---|---|
| Age (years), mean ± SD | 63.2±11.5 | 57.0±13.6 | 64.7±11.0 | 66.4±8.9 | 65.7±10.8 | 62.4±14.1 |
| Age (years), n (%) | ||||||
| <60 | 17 (37.0) | 14 (58.3) | 7 (23.3) | 4 (23.5) | 3 (30.0) | 15 (38.5) |
| 60–75 | 22 (47.8) | 9 (37.5) | 19 (63.3) | 10 (58.8) | 6 (60.0) | 17 (43.6) |
| >75 | 7 (15.2) | 1 (4.2) | 4 (13.3) | 3 (17.6) | 1 (10.0) | 7 (17.9) |
| Gender, n (%) | ||||||
| Male | 28 (60.9) | 8 (33.3) | 16 (53.3) | 8 (47.1) | 5 (50.0) | 23 (59.0) |
| Female | 18 (39.1) | 16 (66.7) | 14 (46.7) | 9 (52.9) | 5 (50.0) | 16 (41.0) |
| PD-L1 status (%), mean ± SD | 19.2±28.6 | 24.0±31.9 | 41.1±37.9 | 56.8±35.1 | 37.1±38.5 | 40.0±38.8 |
| PD-L1 status, n (%) | ||||||
| <1% | 15 (32.6) | 9 (37.5) | 8 (26.7) | 1 (5.9) | 2 (20.0) | 13 (33.3) |
| 1% to 50% | 18 (39.1) | 5 (20.8) | 13 (43.3) | 12 (70.6) | 4 (40.0) | 8 (20.5) |
| >50% | 8 (17.4) | 4 (16.7) | 7 (23.3) | 4 (23.5) | 4 (40.0) | 15 (38.5) |
| Missing | 5 (10.9) | 6 (25.0) | 2 (6.7) | 0 (0.0) | 0 (0.0) | 3 (7.7) |
| ECOG, n (%) | ||||||
| 0 | 23 (50.0) | 12 (50.0) | 13 (43.3) | 7 (41.2) | 5 (50.0) | 15 (38.5) |
| 1 | 7 (15.2) | 3 (12.5) | 1 (3.3) | 2 (11.8) | 2 (20.0) | 4 (10.3) |
| 2 | 3 (6.5) | 0 (0.0) | 2 (6.7) | 1 (5.9) | 0 (0.0) | 1 (2.6) |
| Not available | 13 (28.3) | 9 (37.5) | 14 (46.7) | 7 (41.2) | 3 (30.0) | 19 (48.7) |
Comparison of baseline characteristics and clinicopathological features of patients with the five most common mutations. Group no mutation refers to patients without any detected mutation. Metric variables reported as means with SD with P values from t-test. Categorical variables reported as absolute and relative frequencies with P value from χ2-test and Fisher’s exact test (cell number <6). SD, standard deviation; ECOG, Eastern Cooperative Oncology Group.